Cost-effectiveness evaluation of levodopa/carbidopa/entacapone in treatment of parkinson diseasedoi:10.1016/s1098-3015(11)72604-3R YagudinaAU KulikovVG SerpikValue in Health
A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK Evaluation of cost-effectiveness of levodopa/carbidopa intestinal gel (LCIG), compared to standard care (SC) in patients with advanced Parkinson's disease ......
To review the evidence for efficacy, safety, and cost-effectiveness of levodopa/carbidopa/entacapone (LCE) compared with levodopa/dopa-decarboxyiase inhibitor (DDCI) for Parkinson's disease (PD). PubMed, Embase, the Cochrane Library, and Chinese databases WangFang Data, Chinese Sci-tech Journals...
Palhagen, S. E. et al. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson’s disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.Parkinsonism Relat. Disord.29, 17–23 (2016). Puente, V. e...
This study evaluated the effectiveness of carbidopa/levodopa enteral suspension (CLES) and deep brain stimulation (DBS) on reducing pill burden in APD patients. Methods:We utilized 100% Medicarefee-for-service claims from 2014 to 2018 linked to CLES Patient Support Program (PSP) data. CLES ...
Evaluation of cost-effectiveness of levodopa/carbidopa intestinal gel (LCIG), compared to standard care (SC) in patients with advanced Parkinson's disease (aPD) in the UK.Markov model to quantify costs and outcomes associated with LCIG versus SC in aPD patients at Hoehn and Yahr (H&Y) stages...
Method: We retrospectively analyzed data on AEs in patients treated with LCIG at a French university medical center. For patients still receiving treatment at last follow-up, effectiveness was assessed according to the Clinical Global Impression (CGI) scale and the Movement Disorders Society - ...
Findley, L.J., Lees A., Apajasalo M., et al. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. Curr Med Res Opin. 2005;21(7):1005-1014.
Cost-effectiveness of levodopa/carbi- dopa/entacapone (Stalevo) compared to standard care in UK Par-kinson's disease patients with wearing-off. Curr Med Res Opin 2005;21:1005-14Findley LJ, Lees A, Apajasalo M, et al. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared ...